Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma

Abstract

BackgroundMatrix metalloproteinases (MMPs) are one of the major classes of proteolytic enzymes involved in tumor invasion and metastasis and are inhibited by naturally occurring tissue inhibitors of metalloproteinases (TIMPs). {AU Query: Please verify that corrections made to previous sentence did not alter intended meaning}. In this study, we examined the expression of MMP-2, MMP-9, membrane-type 1 (MT1)-MMP, TIMP-1, and TIMP-2 in renal tissue samples of renal cell cancer and examined the correlation between their expression and clinicopathological parameters.MethodsRenal tissue samples from 76 patients with renal cell carcinoma were available for this study. To determine the expression of MMP-2, MMP-9, MT1-MMP, TIMP-1, and TIMP-2, semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was carried out on tumor and normal tissues.ResultsMean MMP-2, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 mRNA expression in the renal cell carcinomas was significantly higher than in the normal renal tissue (P <0.05). The RT-PCR data of MMP-2, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 did not show any significant correlation with tumor type or pathologic grade of renal cell carcinoma. MMP-2, MMP-9 and MT1-MMP mRNA expression increased significantly with the TNM stage of the tumor.ConclusionsMean MMP-2, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 mRNA expression in the renal cell carcinomas was significantly higher than in the normal renal tissue.

Manual lymphatic drainage for lymphedema following breast cancer treatment

“…Their selected outcome was LE volume. Our data on LE volume, had we pooled trials across assorted control groups, would concur with Huang 2013 with no significant result for MLD.…”

“…We did not present a global pooled point estimate in our review due to differences across treatment and control groups. By contrast, Huang 2013 reports no effect of MLD. Their selected outcome was LE volume.…”

“…Systematic reviews examining MLD for BCRL present contradictory findings from no benefit (Huang 2013), to small benefit (McNeely 2011), to substantial benefit (Moseley 2007) to inconclusive benefit (Devoogdt 2010). This review is the first to use primarily individual patient data to calculate missing or unreported primary outcomes, and thus explore the current contradictory findings of present reviews.…”

Melatonin inhibits MMP‐9 transactivation and renal cell carcinoma metastasis by suppressing Akt‐MAPKs pathway and NF‐κB DNA‐binding activity

“…The invasion of the basement membrane proceeds through a series of discrete steps, and the degradation of matrix in the basement membrane is largely controlled by activities of various matrix metalloproteinase (MMP) subtypes . MMPs are overexpressed in almost all cancers including RCC and are believed to be a promising therapeutic target for RCC . Among these MMPs, MMP‐2, MMP‐9, and their endogenous inhibitors, namely tissue inhibitor of matrix metalloproteinase (TIMP)‐1 and TIMP‐2, are the most crucial enzymes for controlling the degradation of the main constituent of the extracellular matrix (ECM), type IV collagen, and are deeply involved in cancer invasion and metastasis .…”

Prognostic Value of Matrix Metalloproteinase 9 in Renal Cell Carcinoma

“…В отношении ПКР данные противоречивы. По результатам ряда исследователей экспрессия ММП-9 в клетках опухоли была значительно выше, чем в неизмененной ткани почки, и она была взаимосвязана со стадией по TNM [8,9]. Однако получены и противоположные сведения, свидетельствующие об отсутствии зависимости экспрессии ММП-9 от размера опухолевого узла.…”